Genmab (GMXAY) announced that its collaboration partner, Janssen (JNJ), plans to start a new Phase III study of daratumumab in multiple myeloma. The study will compare subcutaneous daratumumab in combination with lenalidomide versus lenalidomide alone as maintenance treatment in patients with newly diagnosed multiple myeloma who are minimal residual disease, or MRD, positive after frontline autologous stem cell transplant. The primary end point of the study is MRD conversion rate, from MRD positive to MRD negative status, at twelve months. The study is planned to start in the first half of 2019. In August 2012, Genmab granted Janssen an exclusive worldwide license to develop, manufacture and commercialize daratumumab.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.